Company news
Theralink Technologies Inc. (OTC:THER) news
Theralink Technologies Inc. news releases on 6ix. Latest, Sep 27, 2018: OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment…
Press releases & updates
OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer
September 27, 2018
OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov
July 9, 2018
OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
July 2, 2018
OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients
June 20, 2018
OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
June 6, 2018
OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial
March 28, 2018
Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial
March 22, 2018
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
March 20, 2018
OncBioMune Appoints Robert Neal Holcomb to Board of Directors
March 19, 2018
OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
March 8, 2018
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
February 28, 2018
OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
February 26, 2018
OncBioMune Provides Update on Market Activity
February 16, 2018
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
February 5, 2018
70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
January 10, 2018
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
December 21, 2017
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
December 5, 2017
80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
November 13, 2017
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
October 17, 2017
OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia
September 29, 2017
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
September 14, 2017
OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
August 31, 2017
OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
August 29, 2017
Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
August 24, 2017
OncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico
August 22, 2017
OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico
August 10, 2017
OncBioMune Submits Application to Commercialize Anti-Rabies Drug in Mexico
August 3, 2017
OncBioMune Acquires Propolis Product Line for German Partner
July 20, 2017
Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement
July 13, 2017
OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico
June 28, 2017
Enrollment to Begin in OncBioMune's Trial of ProscaVax for Prostate Cancer in Mexico
June 27, 2017
OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
June 21, 2017
OncBioMune Awarded Patent for ProscaVax in Japan
June 20, 2017
OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico
June 19, 2017
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)
June 15, 2017
OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong
June 7, 2017
OncBioMune's Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility
June 6, 2017
Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer
June 1, 2017
OncBioMune Reports Record Monthly Sales for Bekunis(R) in May
May 31, 2017
OncBioMune Receives Approval for Male Fertility Product in Mexico
May 30, 2017
OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia
May 23, 2017
OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated
May 9, 2017
OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer
May 3, 2017
OncBioMune, AqVida Partner for Commercializing Cancer and Other Generic Drugs in Mexico
April 26, 2017
OncBioMune Licenses Tretinoin for the Treatment of Acute Promyelocytic Leukemia Throughout Mexico, Central and Latin America
April 20, 2017
OncBioMune Prepares Submission Seeking Marketing Approval for Anti-D Immunoglobulin in Mexico
April 18, 2017
OncBioMune and Gem Pharmaceuticals Finalizing Partnership Terms to Develop New Cancer Drug for Mexico, Central and Latin America Markets
March 30, 2017
OncBioMune Sales of Bekunis(R) and Cirkused(R) Exceed Forecast by 164 Percent in First Six Months on Market
March 27, 2017
OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico
March 20, 2017
OncBioMune Announces Term Sheet with EOC Pharma for Development of Telatinib
March 14, 2017